300 filings
Page 5 of 15
8-K
0kj7f3pd4ivgo5o
15 Apr 21
Regulation FD Disclosure
1:30pm
CT ORDER
iogeo7hgc15jt1
7 Apr 21
Confidential treatment order
12:00am
S-8
w3b74b40c4m
11 Mar 21
Registration of securities for employees
4:42pm
8-K
cyno76yyw6 6norbvitx
11 Mar 21
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
4:02pm
8-K
0l2wn
1 Mar 21
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:28pm
424B5
95biv9sb
1 Mar 21
Prospectus supplement for primary offering
5:23pm
8-K
2uq2ipz7d6 6iifa470z
26 Feb 21
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
4:41pm
8-K
qk03u
12 Feb 21
Entry into a Material Definitive Agreement
5:01pm
8-K
e13ujp
1 Feb 21
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
4:46pm
8-K
x14m8qs p4ajk
14 Dec 20
Nabriva Therapeutics Announces Proposed Public Offering
4:25pm
424B5
xf07b u3uonoy9gttoi
11 Dec 20
Prospectus supplement for primary offering
5:26pm
424B5
ponag
10 Dec 20
Prospectus supplement for primary offering
5:19pm
8-K
3lvlt
7 Dec 20
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
7:30am
8-K
6cwl0ql4f4rws7cy
3 Dec 20
Material Modifications to Rights of Security Holders
6:04am
8-K
4xvmuqt0krhvjue70 sd
5 Nov 20
Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:06pm
EFFECT
wdrzq
14 Sep 20
Notice of effectiveness
12:15am
CORRESP
8bmj yd4rsyqakn4zmx
9 Sep 20
Correspondence with SEC
12:00am
UPLOAD
a87qz3idfw190isvnv3m
8 Sep 20
Letter from SEC
12:00am